skip to main content

Valproate pregnancy prevention — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCNS TherapeuticsValproate pregnancy preventionGPhC CRA

A woman of childbearing potential taking valproate asks whether routine monitoring matters if she is not planning pregnancy. What monitoring is required?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Pregnancy prevention programme requirements and specialist review documentation

Valproate is highly teratogenic and use in people who could become pregnant is subject to strict safeguards. The best answer addresses the key safety, legal or pharmaceutical care issue in the vignette. The other options would either delay appropriate care, create a new risk, or fail to resolve the issue. This is consistent with the cited UK reference for safe pharmacy practice.

Reference: BNF; NICE CKS